IRIS
PALLADINI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.667
AS - Asia 7.708
EU - Europa 5.636
SA - Sud America 1.008
AF - Africa 362
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 24.403
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.430
CN - Cina 3.242
SG - Singapore 1.883
IE - Irlanda 1.480
HK - Hong Kong 975
BR - Brasile 751
VN - Vietnam 732
RU - Federazione Russa 700
FI - Finlandia 617
DE - Germania 612
UA - Ucraina 476
IT - Italia 408
FR - Francia 399
GB - Regno Unito 281
SE - Svezia 259
ZA - Sudafrica 239
IN - India 207
CA - Canada 124
BD - Bangladesh 96
AR - Argentina 85
JP - Giappone 73
MX - Messico 73
IQ - Iraq 66
TR - Turchia 64
PL - Polonia 63
ES - Italia 57
PK - Pakistan 51
NL - Olanda 47
AT - Austria 45
ID - Indonesia 39
CO - Colombia 38
VE - Venezuela 37
BE - Belgio 36
EC - Ecuador 34
PH - Filippine 34
MA - Marocco 31
SA - Arabia Saudita 30
LT - Lituania 24
CL - Cile 20
CZ - Repubblica Ceca 20
IR - Iran 18
TN - Tunisia 17
UZ - Uzbekistan 17
AE - Emirati Arabi Uniti 16
AU - Australia 15
EG - Egitto 15
GR - Grecia 15
MY - Malesia 15
KZ - Kazakistan 14
TH - Thailandia 14
JO - Giordania 13
AL - Albania 12
KE - Kenya 12
LB - Libano 12
PY - Paraguay 12
AZ - Azerbaigian 11
IL - Israele 11
RO - Romania 11
UY - Uruguay 11
BG - Bulgaria 10
JM - Giamaica 10
ET - Etiopia 9
MU - Mauritius 9
PE - Perù 9
BO - Bolivia 8
CH - Svizzera 8
KG - Kirghizistan 8
KR - Corea 8
PS - Palestinian Territory 8
PT - Portogallo 8
DZ - Algeria 7
DK - Danimarca 6
LV - Lettonia 6
SK - Slovacchia (Repubblica Slovacca) 6
EU - Europa 5
NG - Nigeria 5
PA - Panama 5
SY - Repubblica araba siriana 5
BH - Bahrain 4
BN - Brunei Darussalam 4
CU - Cuba 4
IS - Islanda 4
KH - Cambogia 4
NP - Nepal 4
AM - Armenia 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
EE - Estonia 3
GE - Georgia 3
HN - Honduras 3
HU - Ungheria 3
KW - Kuwait 3
MK - Macedonia 3
MN - Mongolia 3
NO - Norvegia 3
OM - Oman 3
QA - Qatar 3
RS - Serbia 3
SN - Senegal 3
Totale 24.351
Salva come PNG Salva come JPEG
Città #
Dublin 1.479
Chandler 1.325
Singapore 989
Hong Kong 947
San Jose 925
Ashburn 866
Dallas 830
Jacksonville 661
Beijing 649
Nanjing 570
Boardman 357
Lauterbourg 288
Helsinki 263
Ho Chi Minh City 260
Princeton 259
Lawrence 251
Nanchang 250
Los Angeles 249
Medford 238
Wilmington 209
Johannesburg 207
Hanoi 189
Shenyang 181
Changsha 162
Hebei 162
Ann Arbor 143
New York 142
Jiaxing 132
Munich 132
Buffalo 125
Redondo Beach 121
Tianjin 117
Shanghai 105
Moscow 103
Hangzhou 97
Pavia 91
São Paulo 79
Milan 78
Piscataway 67
Tokyo 65
Woodbridge 64
Orem 57
Santa Clara 55
Norwalk 51
Warsaw 51
Montreal 50
Frankfurt am Main 47
Turku 45
Denver 44
London 44
Seattle 44
Chennai 43
Da Nang 40
Falkenstein 38
The Dalles 38
Council Bluffs 37
Nuremberg 37
Chicago 35
Toronto 35
Brussels 34
Guangzhou 33
Houston 33
Stockholm 32
Brooklyn 31
Pune 31
Atlanta 30
Fairfield 30
Haiphong 29
San Francisco 28
Poplar 27
Baghdad 25
Amsterdam 24
Manchester 24
Rio de Janeiro 24
Zhengzhou 24
Mexico City 23
Ningbo 23
Boston 22
Phoenix 22
Verona 22
Brasília 21
Des Moines 21
Vienna 21
Charlotte 20
Ankara 19
Columbus 17
Curitiba 16
Dhaka 16
Kunming 16
Washington 16
Caracas 15
Medellín 15
Belo Horizonte 14
Lahore 14
Querétaro 14
Tashkent 14
Hyderabad 13
Jinan 13
Amman 12
Bangkok 12
Totale 16.108
Salva come PNG Salva come JPEG
Nome #
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 154
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 147
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 146
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 145
Chronic intestinal pseudo-obstruction secondary to al amyloidosis associated with severe gastroparesis: case report 139
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 137
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy 137
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 135
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 133
Amyloid typing: immunoelectron microscopy 132
AMICA: an electronic patient record specifically designed for an amyloidosis network 129
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 129
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 128
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 128
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 127
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 127
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 126
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 125
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 123
A patient with AL amyloidosis with negative free light chain results 123
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 123
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 122
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 122
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 121
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 120
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 120
Cardiac light chain amyloidosis: The role of metal ions in oxidative stress and mitochondrial damage 120
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 119
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 119
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 119
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 119
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 118
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 118
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 118
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis 118
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 117
Bortezomib-induced paralytic ileus is a potential gastrointestinal side-effect of this first-in-class anti-cancer proteasome inhibitor 116
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 116
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 115
Clotting alterations in primary systemic amyloidosis. 115
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 115
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 115
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 114
A practical approach to the diagnosis of systemic amyloidoses 114
Bone marrow amyloidosis. 113
Hereditary amyloidosis 112
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 110
Holter monitoring in AL amyloidosis: prognostic implications. 110
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 110
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 110
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 109
Biochemical markers in early diagnosis and management of systemic amyloidoses 108
4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis 108
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 108
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 106
Valore prognostico della presenza di disturbi della conduzione cardiaca nei pazienti affetti da amiloidosi AL 106
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 106
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 106
Thalidomide plus intermediate-dose dexametasone is an effective but toxic treatment for patients with AL (primary) amyloydosis 106
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 106
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 105
AMICA: an electronic patient record specifically designed for an amyloidosis network. 105
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 105
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 105
Prognostication of survival and progression to dialysis in AA amyloidosis 105
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 104
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 104
A workflow management system for the biological samples exchange within the amyloidosis network 104
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 103
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis. 103
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin in primary amyloidosis (AL) 103
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 103
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 102
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44 102
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 102
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 101
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 100
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 100
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 99
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 99
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis 99
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 98
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 98
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 98
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 98
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 98
A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options 98
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 97
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 97
Sjögren’s syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? 96
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 96
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in- class anticancer proteasome inhibitor. 96
Clinical aspects of systemic amyloid diseases. 95
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 95
Light chain amyloidosis 2012: a new era. 95
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 95
Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult. 94
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis 94
A workflow management system for the biological samples exchange within the amyloidosis network 93
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 93
Totale 11.214
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.451
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.451
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021303 0 0 0 0 0 0 0 0 0 147 126 30
2021/20221.102 21 10 26 11 32 19 11 91 61 42 155 623
2022/20233.826 436 278 47 286 351 350 24 211 1.690 20 85 48
2023/20241.412 181 304 48 109 126 295 33 86 12 43 100 75
2024/20254.073 85 295 96 111 70 283 201 254 990 181 479 1.028
2025/20269.720 774 723 1.049 1.208 1.432 419 1.949 518 1.032 616 0 0
Totale 24.900